Novavax COVID-19 vaccine gets expanded CMA recommendation in the EU

Novavax Inc.

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

This is not a CAPTIS article. Originally, it was published here.